MedTrace Logo

Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia

NCT00407329 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2013-11-06

No results posted yet for this study

Summary

We hypothesize that the absolute or relative serum or urine levels of the urokinase plasminogen activator system, including uPA, uPAR and PAI-1,2 (inhibitors of the uPAR/uPA complex), are associated with inflammation in prostatic tissue.

Conditions

  • BPH

Interventions

PROCEDURE

transurethral resection of the prostate

resection of prostate

Sponsors & Collaborators

  • Queen's University

    lead OTHER

Principal Investigators

  • J. Curtis Nickel, MD FRCSC · Queen's Universtiy

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-02-29
Completion
2012-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00407329 on ClinicalTrials.gov